Related references
Note: Only part of the references are listed.Myeloid neoplasms post PARP inhibitors for ovarian cancer
Giuseppe Caruso et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study
Laura Vertechy et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
S. I. Labidi-Galy et al.
ANNALS OF ONCOLOGY (2023)
Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis
Min-Hyun Baek et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ ENGOT-OV26/GOG-3012 study
Roisin E. O'Cearbhaill et al.
GYNECOLOGIC ONCOLOGY (2022)
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups
Clorinda Schettino et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit et al.
LANCET ONCOLOGY (2022)
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J. S. Frenel et al.
ANNALS OF ONCOLOGY (2022)
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis
Karen Cadoo et al.
GYNECOLOGIC ONCOLOGY (2022)
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
Melissa M. Hardesty et al.
GYNECOLOGIC ONCOLOGY (2022)
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance
Eleonora Palluzzi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)
BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.
Natalia Lukashchuk et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
Florian Heitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Ignace Vergote et al.
LANCET ONCOLOGY (2022)
PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety
A. J. Gonzalez Martin et al.
ANNALS OF ONCOLOGY (2022)
NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP ebevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery
G. Freyer et al.
ANNALS OF ONCOLOGY (2022)
Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
G. Thibault et al.
ANNALS OF ONCOLOGY (2022)
EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Panagiotis A. Konstantinopoulos et al.
FUTURE ONCOLOGY (2022)
MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297)
Kathleen Moore et al.
GYNECOLOGIC ONCOLOGY (2022)
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)
Ning Li et al.
GYNECOLOGIC ONCOLOGY (2022)
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting
Margarita Romeo et al.
CANCERS (2022)
OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA
Robert L. Coleman et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)
PATTERNS OF INITIAL OVARIAN CANCER RECURRENCE ON NIRAPARIB MAINTENANCE MONOTHERAPY IN PATIENTS WITH NO BASELINE EVIDENCE OF DISEASE FOLLOWING FIRST-LINE CHEMOTHERAPY: PRIMA/ENGOT-OV26/GOG-3012 POST-HOC SUBGROUP ANALYSIS
M. Kamavra et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial
Jung-Yun Lee et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2022)
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Osnat Elyashiv et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote et al.
EUROPEAN JOURNAL OF CANCER (2021)
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
Payal D. Shah et al.
GYNECOLOGIC ONCOLOGY (2021)
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Lucia Musacchio et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J. Monk et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
The systemic treatment of recurrent ovarian cancer revisited
T. Baert et al.
ANNALS OF ONCOLOGY (2021)
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
P. Harter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Sandro Pignata et al.
LANCET ONCOLOGY (2021)
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial
Tingyan Shi et al.
LANCET ONCOLOGY (2021)
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
Sabrina Chiara Cecere et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
Paul DiSilvestro et al.
CANCERS (2021)
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher et al.
NATURE COMMUNICATIONS (2021)
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer
Ursula Matulonis et al.
GYNECOLOGIC ONCOLOGY (2021)
EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.
Shannon Neville Westin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
Antonio Gonzalez Martin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF UPIFITAMAB RILSODOTIN, A NAPI2B-DIRECTED ADC IN PLATINUM-RESISTANT OVARIAN CANCER
N. Concin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Sabrina Chiara Cecere et al.
GYNECOLOGIC ONCOLOGY (2020)
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Richard T. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2020)
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer et al.
LANCET ONCOLOGY (2020)
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N. Colombo et al.
ANNALS OF ONCOLOGY (2020)
Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
D. M. O'Malley et al.
ANNALS OF ONCOLOGY (2020)
PARP inhibitor resistance: the underlying mechanisms and clinical implications
He Li et al.
MOLECULAR CANCER (2020)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
ANNALS OF ONCOLOGY (2019)
ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
Ignace Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.
Philipp Harter et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
Anne-Claire Hardy-Bessard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore et al.
LANCET ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Robert L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference
Gavin C. E. Stuart et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Share Paper
